Highlights Newsletter 2
This newsletter presents you the following key sessions:
1. Adjuvant pembrolizumab improves DFS in high-risk muscle-invasive urothelial carcinoma
2. ctDNA as a predictive biomarker for disease monitoring in non-seminomatous germ-cell tumours